Vigabatrin

Epilepsia

Volumn 36, Issue , 1995, Pages S95-S104

  Ben‐Menachem, Elinor ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adverse effects; Anticonvulsants; Clinical trials; Epilepsy; Seizures; Vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; VIGABATRIN;

4 AMINOBUTYRIC ACID METABOLISM; AGITATION; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EPILEPSY; HUMAN; HYPERKINESIA; MAJOR CLINICAL STUDY; NEUROTRANSMISSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CHILD; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DIZZINESS; DRUG ADMINISTRATION SCHEDULE; EPILEPSY; FATIGUE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MICE; RATS; RECEPTORS, GABA; SLEEP STAGES; TREATMENT OUTCOME; VIGABATRIN;

EID: 0029069355     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1995.tb06003.x     Document Type: Article

References (70)

1. The role of vigabatrin in the management of infantile epileptic syndromes
2. Effect of long‐term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system–a case study
3. Effect of long‐term vigabatrin therapy on selected CSF neurotransmitter concentrations.
4. Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5‐hydroxyin‐doleacedic acid in patients with complex partial seizures
5. Vigabatrin: clinical evidence supporting rational polytherapy in management of uncontrolled seizures
6. Vigabatrin for refractory complex partial seizures: multicenter single‐blind study and long‐term follow‐up
7. Multicenter long‐term safety and efficacy study of vigabatrin for refractory complex partial seizures; an update
8. Neuropathology findings in patients receiving long‐term vigabatrin therapy for chronic intractable epilepsy
9. Passage of S(+) and R(‐) gamma‐vinyl‐GABA across the human isolated perfused placenta
10. Therapeutic trial of vigabatrin in refractory infantile spasm.
11. Vigabatrin in complex partial seizures: a long‐term study
12. Occlusion and metabolism of gamma‐aminobutyric acid by brain tissue
13. Clinical results of vigabatrin treatment in patients with refractory epilepsy.
14. Results of a multicenter, placebo‐controlled, parallel study of vigabatrin (VGB, Sabril) in patients with focal epilepsy whose seizures are difficult to control
15. Role of the substantia nigra in GABA‐mediated anticonvulsant actions
16. Chronic toxicity studies with vigabatrin, a GABA‐transaminase inhibitor
17. Neuropathology of vigabatrin
18. Gamma‐vinyl GABA: a double‐blind, placebo‐controlled trial in partial epilepsy
19. Gamma‐vinyl GABA: a single‐blind trial in patients with epilepsy
20. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy and disorders of motor control
21. Assay of alpha‐difluoro‐methylornithine in body fluids and tissues by automatic amino acid analysis
22. Determination of the R(‐) and S(+) enantiomers of gamma‐vinyl‐gamma‐aminobutyric acid in human body fluids by gas chromatography‐mass spectrometry
23. Pharmacokinetics of vigabatrin: implications of creatinine clearance
24. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S‐en‐antiomer
25. Eight year experience with vigabatrin: clinical neurophysiologic, neuropathology studies
26. Effect of food on the bioavailability of vigabatrin tablets.
27. Quantitative MR relaxometry study of effects of vigabatrin on the brains of epilepsy patients
28. Gamma‐vinyl GABA (4‐amino‐hex‐5‐enoic acid), a new selective irreversible inhibitor of GABA‐T: effects on brain GABA metabolism in mice
29. Randomized controlled pilot study of vigabatrin versus carbamazepine monotherapy in newly diagnosed patients with epilepsy, an interim report
30. Effects of gamma‐vinyl GABA on bicuculline‐induced seizures
31. Effects of long‐term vigabatrin on somatosensory evoked potentials in epileptic patients
32. 4‐Amino‐hex‐5‐enoic acid, a selective catalytic inhibitor of 4‐aminobutyric acid aminotransferase in mammalian brain
33. Double‐blind placebo‐controlled study of vigabatrin (gamma‐vinyl GABA) in drug resistant epilepsy
34. Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA‐transaminase, gamma‐acetylenic GABA (4‐amino‐hex‐5‐ynoic acid) and gamma‐vinyl GABA (4‐amino‐hex‐5‐enoic acid)
35. Single‐blind placebo‐controlled dose modification study of vigabatrin in refractory epileptic patients
36. Long‐term follow‐up study of vigabatrin in the treatment of refractory epilepsy
37. Meta‐analysis of placebo‐controlled studies of vigabatrin in drug resistant epilepsy
38. A profile of vigabatrin
39. Effect of vigabatrin (gamma‐vinyl GABA) on partial attacks of various localizations.
40. The effect of gamma‐vinyl GABA and gamma‐acetylenic GABA on the concentration of homocarnosine in brain and CSF of the rat
41. Multicenter dose‐response study of vigabatrin in adults with focal (partial) epilepsy
42. Intracerebral site of convulsant action of bicuculline
43. β‐endorphin and prolactin levels in human cerebrospinal fluid during the ‐y‐vinyl‐GABA treatment of patients with complex partial epilepsy
44. Efficacy and safety of vigabatrin in the long‐term treatment of refractory epilepsy
45. Double‐blind, placebo‐controlled, cross‐over study of vigabatrin in drug resistant epilepsy of the adult
46. Pharmacokinetics of the individual enantiomers of vigabatrin (gamma‐vinyl GABA) in epileptic children
47. Open, double‐blind and long‐term study of vigabatrin in chronic epilepsy
48. Pharmacology and clinical pharmacology of vigabatrin
49. Vigabatrin in pharmaco‐resistant epilepsies: a single‐blind, placebo‐controlled study.
50. Double‐blind study of gamma‐vinyl GABA in patients with refractory epilepsy
51. Interaction between vigabatrin and phenytoin
52. Vigabatrin: rational treatment for chronic epilepsy
53. Psychophysiological and psychometric studies after manipulating the GABA sys‐tern by vigabatrin, a GABA transaminase inhibitor
54. Vigabatrin.
55. Biochemical and clinical effects of gamma‐vinyl GABA in patients with epilepsy
56. Attempts to correlate alterations in brain GABA metabolism by GABA‐T inhibitors with their anticonvulsant effects.
57. Effect of elevated brain GABA concentrations of the actions of bicuculline and picrotoxin in mice
58. Double‐blind dose reduction study of vigabatrin in complex partial epilepsy
59. Quantitative analysis of vigabatrin in plasma and urine by reversed‐phase high‐performance liquid chromatography
60. Vigabatrin and behavior in patients with psychiatric history
61. Gamma‐vinyl GABA in endopiriform area suppresses kindled amygdala seizures
62. Vigabatrin: effect on in vivo and ex vivo magnetic resonance imaging of dog brains [Abstract]
63. Vigabatrin in the treatment of epilepsy: a double‐blind placebo‐controlled study
64. Vigabatrin in the treatment of epilepsy: a double‐blind placebo‐controlled study
65. Double‐blind study of vigabatrin in the treatment of drug resistant epilepsy
66. Assessment of neurotoxicity of vigabatrin by serial evoked response and psychometric testing in patients with refractory epilepsy
67. Determination of vigabatrin in plasma by reversed‐phase high performance liquid chromatography
68. Vigabatrin induced intramyelinic oedema II: Effects on MRI in dogs